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Abstract 
PIMREG (FAM64) was initially identified as 
CATS, the CALM (PICALM) interacting protein 
expressed in thymus and spleen. Mounting 
evidence suggests the involvement of FAM64A in 
tumorigenesis. Through interaction with PICALM, 
FAM64 was able to influence the subcellular 
localization of the leukemic fusion protein 
PICALM/MTT10 (CALM/AF10). FAM64A is 
highly expressed in leukemia, lymphoma and tumor 
cell lines and its levels are strongly correlated with 
cellular proliferation in both malignant and normal 
cells. FAM64A is a mitotic regulator that controls 
chromosome segregation during cell division, and 
its transcripts covariate with that of cell cycle 
regulation genes in tumorigenesis. Nevertheless, a 
precise role of FAM64A in tumorigenesis is yet to 
be defined. 
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Identity 
Other names: FAM64A, FLJ10156, FLJ10491, 
CATS, RCS1 
HGNC (Hugo): PIMREG 
Location: 17q13.2 
Location (base pair): Starts at 6444415 and ends 
at 6451469 bp from pter (according to hg38 -
Dec2013) 
DNA/RNA 
Description 
PIMREG (FAM64) is located on chromosome 17 
band p13.2, 6.29 megabase pairs from the telomere 
of the short arm (chromosome 17 genomic contig 
NT_010718). The genomic locus spans 7 Kb and 
contains 6 exons with a non-coding first exon. 
Transcription 
Two alternatively spliced transcripts of 1.5 Kb are 
formed (NM_019013 and NM_001195228) and 
code for two protein isoforms of 238 and 248 
amino acids in length (isoform 1 and 2, 
respectively). Both isoforms share the first 228 
residues, encoded by exons 2-4.  
The two proteins differ in their C-termini. The 10 
last amino acids of isoform 1 are encoded by exon 
5, which is absent in the transcript coding for 
isoform 2.  
The last 20 amino acids of isoform 2 are encoded 
by exon 6 (Figure 1) (Archangelo, et al. 2006). An 
additional transcript variant with retained intron 5 
(between exons 5 and 6) was described 
(Archangelo, et al. 2006; Coulombe-Huntington, et 
al. 2009). There are 4 processed pseudogenes of 
FAM64A at other chromosomal locations (2q33, 
4p15, 4q24 and 6q15). 
Protein 
Description 
The FAM64A calculated molecular weight is about 
27 kDa.  
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Figure 1: Genomic organization, alternative splicing, and protein isoforms of PIMREG (FAM64).  Boxes represent exons, 
with blue parts symbolizing coding region and gray parts the 5' and 3' UTRs. There are 2 splice variants (sizes are indicated in 
parentheses). In splice variant 2, exon 5 is spliced out resulting in a longer protein (FAM64A isoform 2) encoded by exons 2, 3, 4 
and 6. The FAM64A isoform 1 (shorter form) is encoded by exons 2, 3, 4 and 5 from splice variants 1 and the transcript with 
retained intron 5 (see in the text). Both FAM64A isoforms are identical from amino acids 1-228, they differ in their last 10 and 20 
C-terminal residues (isoform 1 and 2, respectively). (Figure modified from Archangelo, et al. 2006) 
The protein contains two putative destruction box 
motifs (RxxL) at amino acids 14-17 and 53-56 
(DB1 and DB2, respectively), the second being a 
recognition motif for the ubiquitin ligase anaphase-
promoting complex/cyclosome (APC/C) (Zhao, et 
al. 2008).  
There are three types of posttranslational 
modifications identified within FAM64A isoforms, 
namely lysine- acetylation (K-ac), lysine-
ubiquitination (K-ub) and phosphorylation (S-p and 
T-p). A total of 22 residues were described as 
phosphorylated in FAM64A in a variety of large 
scale proteomic studies as revealed by the 
phosphoproteomic databases PhosphoSitePlus™ 
(http://www.phosphosite.org) and Phosida 
(http://www.phosida.com/) (Figure 2). 
Expression 
In normal adult tissue FAM64A is predominantly 
expressed in thymus, spleen and colon and to a 
lesser extent in small intestines, ovary and brain 
(Archangelo, et al. 2006; Archangelo, et al. 2008). 
Moreover, FAM64A is highly expressed in 
leukemia, lymphoma and tumor cell lines. The 
protein levels vary throughout the cell cycle. In 
synchronized cells FAM64A accumulates in S and 
G2 phases of the cell cycle, peaks in the mitosis and 
drops drastically as cells exit from mitosis into the 
G1 phase (Archangelo, et al. 2008; Zhao, et al. 
2008). FAM64A transcripts covariate with that of 
cell cycle regulation genes in tumorigenesis (Zhao, 
et al. 2008).  
 
 Figure 2: Diagram representing the protein structure of PIMREG (FAM64).  FAM64A is a phosphoprotein. All residues 
described to be phosphorylated in large scale proteomic studies are depicted. Source: Phosphoproteomic databases 
PhosphoSitePlus™ (http://www.phosphosite.org) and Phosida (http://www.phosida.com/). Destruction box motifs are depicted as 
orange boxes (DB1 and DB2). Aminoacids comprising the DB motifs and the unique phospho-residue characterized (S131) are 
shown. (Figure modified from Archangelo, et al. 2013) 
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Resting human peripheral blood lymphocytes 
(PBLs), which are not selected for growth in 
culture, do not express FAM64A protein. 
However, when these cells are induced to 
proliferate upon mitogen activation they do express 
FAM64A. Likewise, glioblastoma cells induced to 
proliferate, show a progressive upregulation of 
FAM64A. Conversely, FAM64A expression 
drastically decreases when highly proliferative 
leukemia cells cease to proliferate upon exposure to 
differentiation agents (Barbutti, et al. 2016).Thus, 
FAM64A expression positively correlates with the 
proliferative state of the cells (Archangelo, et al. 
2008). 
Expression analysis of the murine Fam64a homolog 
revealed a strong expression throughout mouse 
embryogenesis, in particular at the developing 
central nervous system (CNS). The expression 
decreases gradually and proportionally as embryos 
develop to later stages (Archangelo, et al. 2008). In 
the hematopoietic compartment, Fam64A is widely 
expressed in different cell subpopulations 
(Archangelo, et al. 2008). Moreover, RNA-Seq 
analysis of individual hematopoietic stem cells 
(HSCs) to resolve heterogeneity within HSC 
population, revealed that Fam64a is highly 
expressed in the HSC population primed for 
proliferation (Wilson, et al. 2015). 
Localisation 
FAM64A is a nuclear protein enriched in the 
nucleoli. Expression levels in the nucleoplasm and 
nucleolar accumulation are different from cell to 
cell and dependent on the cell cycle phase 
(Archangelo, et al. 2008) (Figure 3). In mitotic cells 
FAM64A-GFP is diffusely distributed throughout 
cells without specific association with 
chromosomes, kinetochores, spindle, or centrosome 
(Zhao, et al. 2008). 
Function 
Based on the fact that levels of FAM64A protein 
strongly correlate with cellular proliferation in both 
normal and malignant cells, this protein was 
described as a marker for proliferation with a 
possible role in the control of cell proliferation and 
tumorigenesis (Archangelo, et al. 2008). In fact, 
silencing of FAM64A protein in the U937 leukemia 
cell line resulted in reduced proliferation and 
altered cell cycle progression, as attested by 
diminished expression of the cell cycle regulators 
CCNA1, CCNE1, CCNB1 (cyclin-A, -E and -B1) 
in FAM64A depleted cells (Barbutti, et al. 2016). 
Furthermore, Zhao and coworkers described 
FAM64A as a regulator of chromosome 
segregation. FAM64A is a substrate of the APC/C 
complex that controls the metaphase to anaphase 
transition and its knock-down resulted in 
accelerated anaphase onset. Thus FAM64A plays 
an important role in determining the kinetics of 
mitotic progression (Zhao, et al. 2008). Although 
the literature indicates a putative function of 
FAM64A in controlling cell cycle progression, 
division and tumorigenesis, the impairment of cell 
proliferation upon FAM64A depletion was modest 
and not sufficient to inhibit tumor growth of 
xenotransplanted U937 cells in an in vivo model 
(Barbutti, et al. 2016). Similarly, the faster 
metaphase-to-anaphase transition observed in 
FAM64A depleted cells was not sufficient to 
produce any of the mitotic defects often observed in 
cancer cells. Rather, mitotic index, spindle 
assembly, chromosome congregation/segregation 
and cytokinesis proceeded normally in FAM64A 
depleted cells (Zhao, et al. 2008). 
FAM64A has also been described to function as a 
transcriptional repressor in a GAL4-based reporter 
gene assay (Archangelo, et al. 2006). Additionally, 
FAM64A was able to repress the transactivation 
capacity of the leukemic fusion protein 
PICALM/MTT10 (CALM/AF10) (Archangelo, et 
al. 2013). Evidence further supporting the 
transcriptional inhibitory properties of FAM64A 
were provided by Zhao and colleagues, who 
described the interaction between FAM64A and 
components of the nucleosome remodeling and 
deacetylase (NuRD) complex, such as MTA2, 
HDAC1/HDAC2 and RBBP7 / RBBP4 
(RBAp46/48) (Zhao, et al. 2008). 
 
Figure 3: Subcellular localization of endogenous PIMREG (FAM64). Endogenous protein was visualized by 
immunofluorescence and confocal microscopy in non-synchronized U2OS cells. FAM64A is a nuclear protein enriched in the 
nucleolus of some cells. Note the different levels of FAM64A expression from cell to cell. FAM64A protein levels and nucleolar 
localization are cell cycle dependent. The figure shows cells labeled with Cy3 (FAM64A) and DAPI with channels merged. 
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The NuRD complex is implicated in transcriptional 
regulation and plays a role in modifying chromatin 
structures to initiate and maintain gene repression. 
Since its discovery a number of FAM64 interacting 
proteins have been described (e.g. PICALM 
(Archangelo, et al. 2006), UHMK1 (KIS) 
(Archangelo, et al. 2013), PRNP (PrPC) (Satoh, et 
al. 2009), PTBP3 (ROD1) (Brazao, et al. 2012) and 
NuRD complex (Zhao, et al. 2008), shedding light 
on the putative function of this protein. 
The interaction of FAM64A with the 
Phosphatidylinositol Binding Clathrin Assembly 
Protein (PICALM) was identified in a yeast two 
hybrid screen (Y2H) and confirmed by GST pull-
down and co-immunoprecipitation experiments for 
both FAM64A isoforms. The FAM64A interaction 
region was mapped to amino acids 221 to 294 of 
PICALM. Through this interaction FAM64A was 
able to alter the subcellular localization of 
PICALM. The fluorescently-tagged protein YFP-
PICALM localized mainly in the cytoplasm and 
plasma membrane of transfected NIH3T3 cells. 
However, when CFP-FAM64A was co-expressed, 
PICALM was observed both at the 
cytoplasm/membrane and in the nucleus of some 
cells at almost equal levels (Archangelo, et al. 
2006). The interaction between FAM64A and the 
Kinase Interacting Stathmin (KIS and UHMK1) 
was identified in Y2H screen and confirmed by 
GST pull-down, co-immunoprecipitation and co-
localization experiments. KIS interacts with amino-
acids 136-187 of FAM64A. Kinase assay showed 
that FAM64A is a substrate of KIS at serine 131 
(S131). In a GAL4-based reporter gene assay KIS 
enhanced the transcriptional repressor activity of 
FAM64A, independently of phosphorylation on 
S131 but dependent on KIS kinase activity 
(Archangelo, et al. 2013). RNA 
immunoprecipitation sequencing (RIP-seq) 
described the interaction between FAM64A and 
ROD1 (PTBP3), an RNA-binding protein involved 
in nonsense-mediated decay (NMD) (Brazao, et al. 
2012). Protein microarray analysis identified 
FAM64A as an interacting partner of the cellular 
prion protein (PrPC). The interaction was 
confirmed by co-immunoprecipitation of the 
overexpressed tagged-proteins (Satoh, et al. 2009). 
Homology 
The human FAM64A shares homology with the 
species described in Table 1. 
Mutations 
Somatic 
Mutations in the FAM64A gene were reported in 
the catalogue of somatic mutations in cancer 
(COSMIC) database in 53 out of the 28710 samples 
tested, of which 6 are nonsense substitutions, 33 
missense substitutions and 10 synonymous 
substitutions 
(http://cancer.sanger.ac.uk/cancergenome/projects/c
osmic) 
Homo sapiens 
FAM64A 
Symbol 
Identity (%) 
Protein 
DNA 
vs. P.troglodytes  FAM64A 96.6 98.6 
vs. vs. M. mulatta LOC712701  91.6  95.9 
vs. C. lupus FAM64A 73.3 81.2  
vs. B. taurus FAM64A 83.2  85.9 
vs. M. musculus Fam64a 74.8  77.5 
vs. R. norvegicus Fam64a 76.7 79.1 
Table 1. Homology between the human FAM64A and other 
species (Source: http://www.ncbi.nlm.nih.gov/homologene/) 
Implicated in 
Leukemia 
FAM64A is highly expressed in leukemia and 
lymphoma cell lines (Archangelo, et al. 2008). 
FAM64A interacts with the central domain of 
PICALM, a region contained in the PICALM 
moiety of the PICALM/MLLT10 (CALM/AF10) 
leukemic fusion protein (Archangelo, et al. 2006). 
FAM64A expression markedly increased the 
nuclear localization of PICALM/MLLT10 
(CALM/AF10) and counteracted the ability of this 
fusion protein to activate transcription in vitro 
(Archangelo, et al. 2006; Archangelo, et al. 2013). 
Additionally, the murine Fam64a transcripts were 
up-regulated in hematopoietic cells (B220+ 
lymphoid cells) transformed by PICALM/MLLT10 
(CALM/AF10) in comparison to the same 
subpopulation from non-leukemic mice 
(Archangelo, et al. 2008).  
In a recent report, FAM64A silencing in the 
PICALM/MLLT10 (CALM/AF10)-positive U937 
leukemia cell line resulted in somewhat reduced 
proliferation, altered cell cycle progression, lower 
migratory ability in vitro, and reduced 
clonogenicity of FAM64A-depleted U937 cells. 
Nonetheless, FAM64A silencing was not capable of 
interfering with the expression of the 
PICALM/MLLT10 (CALM/AF10)-leukemia 
deregulated genes (HOXA gene cluster, MEIS1 and 
BMI1) nor sufficient to hinder tumor growth of 
U937 xenografts (Barbutti, et al. 2016). 
Breast cancer 
FAM64A was identified together with BIRC5 and 
CENPA as the three genes specifically upregulated 
in triple-negative breast cancer (TNBC), an 
aggressive type of cancer with poor outcome and 
short survival. In a broader clinical set analysis, 
PIMREG (PICALM interacting mitotic regulator) Archangelo LF. 
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FAM64A upregulation correlated with poor 
survival, despite the molecular type of breast cancer 
(Zhang, et al. 2014). 
Lung cancer 
The fusion gene XAF1 (17p13.1) / FAM64A 
(17p13.2) was identified in a single lung 
adenocarcinoma patient from a large scale RNA 
sequencing study. The fusion gene was validated by 
Sanger sequencing and showed no co-occurrence 
with other canonical driver point mutation in that 
sample. The breakpoints were described at position 
chr17:6663920, within exon 4 of the donor 
transcript (XAF1), and at position chr17:6348396, 
within the 5' untranslated region (5'UTR) of the 
acceptor gene FAM64A (Seo, et al. 2012).  
In the same study FAM64A was also detected 
among a number of cancer outlier genes (CoGs), 
being highly expressed in 8 cancer tissue samples 
(Seo, et al. 2012). 
Head and Neck squamous cell 
carcinoma 
Single gene clustering of RNA sequencing in a set 
of 177 lung and 279 head and neck squamous cell 
carcinomas, reveled a differential alternative 
isoform usage pattern of the FAM64A locus, with 
lower expression of a 152 bp cluster within the final 
exon of the gene. The implication of the differential 
isoform usage remains to be determined (Kimes, et 
al. 2014). 
To be noted 
FAM64A is a marker for proliferation (Archangelo, 
et al. 2008) with potential use as a prognostic 
marker (Zhang, et al. 2014). FAM64A plays a role 
in the regulation of chromosome segregation during 
cell division (Zhao, et al. 2008) and in the control 
of cell cycle progression and clonogenicity of the 
U937 leukemia cell line (Barbutti, et al. 2016). 
However, FAM64A depletion is not sufficient to 
impair either mitosis or hinder cell growth 
(Barbutti, et al. 2016; Zhao, et al. 2008). Hence, it 
still to be addressed whether the strong correlation 
of FAM64A expression with proliferation is 
determinant for tumorigenesis or if it is a 
consequence. 
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